National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
R35 Outstanding Investigator Award
- April 04, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25, 2025. See Notice NOT-OD-24-084
- November 18, 2024 - Notice of Change to Budget Information for New Investigators in PAR-22-180 Maximizing Investigators' Research Award (R35 - Clinical Trial Optional). See Notice NOT-GM-25-008.
- September 10, 2024 - Notice of Change to Reduce the Required Effort Level for Program Directors/Principal Investigators in PAR-22-180 Maximizing Investigators' Research Award (R35 - Clinical Trial Optional) . See Notice NOT-GM-24-054
- February 23, 2024 - Notice to Clarify the Eligibility Criteria of Program Directors/Principal Investigators in PAR-22-180. See Notice NOT-GM-24-026
- December 13, 2023 - Notice of Change to Budget Instructions in PAR-22-180 "Maximizing Investigators' Research Award (R35 - Clinical Trial Optional)". See Notice NOT-GM-24-012
- NOT-OD-23-012 Reminder: FORMS-H Grant Application Forms and Instructions Must be Used for Due Dates On or After January 25, 2023 - New Grant Application Instructions Now Available
- NOT-GM-23-003 - Notice of Informational Webinar for PAR-22-180
- NOT-OD-22-190 - Adjustments to NIH and AHRQ Grant Application Due Dates Between September 22 and September 30, 2022
- June 06, 2022 - Notice of Special Interest (NOSI): Understanding and Addressing the Impact of Structural Racism and Discrimination on Biomedical Career Progression and the Biomedical Research Enterprise. See Notice NOT-GM-21-033
See Notices of Special Interest associated with this funding opportunity
The Maximizing Investigators' Research Award (MIRA) provides support for the program of research in an investigator's laboratory that is within the mission of NIGMS. The goal of MIRA is to increase the efficiency and efficacy of NIGMS funding. It is anticipated that this program will:
- Increase the stability of funding for NIGMS-supported investigators, which could enhance their ability to take on ambitious scientific projects and approach problems more creatively;
- Increase flexibility for investigators to follow important new research directions within the NIGMS mission as opportunities arise, rather than being bound to specific aims proposed in advance of the studies;
- More widely distribute funding among the nation's highly talented and promising investigators to increase overall scientific productivity and the chances for important breakthroughs;
- Reduce the time spent by researchers writing and reviewing grant applications, allowing them to spend more time conducting research;
- Enable investigators to devote more time and energy to mentoring trainees in a more stable research environment.
This FOA allows applications from eligible NIGMS-funded investigators and from New Investigators proposing research within the scientific mission of NIGMS. The FOA also allows renewal applications from all current MIRA grantees (established investigators and those previously funded as early-stage investigators). PD/PIs who are currently Early Stage Investigators (ESIs) should apply through the ESI MIRA FOA and should not apply through this FOA.
Not Applicable
| Application Due Dates | Review and Award Cycles | ||||
|---|---|---|---|---|---|
| New | Renewal / Resubmission / Revision (as allowed) | AIDS | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
| January 17, 2023 | January 17, 2023 | Not Applicable | July 2023 | October 2023 | December 2023 |
| May 16, 2023 | May 16, 2023 | Not Applicable | November 2023 | January 2024 | April 2024 |
| January 16, 2024 | January 16, 2024 | Not Applicable | July 2024 | October 2024 | December 2024 |
| May 16, 2024 | May 16, 2024 | Not Applicable | November 2024 | January 2025 | April 2025 |
| January 16, 2025 | January 16, 2025 | Not Applicable | July 2025 | October 2025 | December 2025 |
| May 16, 2025 | May 16, 2025 | Not Applicable | November 2025 | January 2026 | April 2026 |
All applications are due by 5:00 PM local time of applicant organization.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Not Applicable
It is critical that applicants follow the instructions in the Research (R) Instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from NIH Guide for Grants and Contracts).
Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions.
Applications that do not comply with these instructions may be delayed or not accepted for review.
There are several options available to submit your application through Grants.gov to NIH and Department of Health and Human Services partners. You must use one of these submission options to access the application forms for this opportunity.
- Use the NIH ASSIST system to prepare, submit and track your application online.
- Use an institutional system-to-system (S2S) solution to prepare and submit your application
to Grants.gov and eRA Commons to track your
application. Check with your institutional officials regarding availability.
- Use Grants.gov Workspace to prepare and submit your application and eRA Commons to track your application.
Purpose
Supporting fundamental research by funding individual projects has a number of consequences that reduce the efficiency and effectiveness of the biomedical research enterprise in the U.S. To address these issues and increase the efficiency and efficacy of grant funding, the NIGMS Maximizing Investigators' Research Award (MIRA) is a single grant to provide support for the NIGMS-relevant program of research in an investigator's laboratory. For this FOA, the "program of research" is defined as a collection of projects in an investigator's laboratory that are within the mission of NIGMS.
It is anticipated that MIRA will achieve the following:
- Increase the stability of funding for NIGMS-supported investigators, which could enhance their ability to take on ambitious scientific projects and approach problems more creatively;
- Increase flexibility for investigators to follow important new research directions within the NIGMS mission as opportunities arise, rather than being bound to specific aims proposed in advance of the studies;
- More widely distribute funding among the nation's highly talented and promising investigators to increase overall scientific productivity and the chances for important breakthroughs;
- Reduce the time spent by researchers writing and reviewing grant applications, allowing them to spend more time conducting research;
- Reduce the administrative burden associated with a PD/PI managing multiple NIGMS research grants; and
- Enable PD(s)/PI(s) to devote more time and energy to mentoring junior scientists in a more stable research environment.
This FOA allows new applications from eligible PDs/PIs as defined in the eligibility section (Section III. 1) and renewals of all active NIGMS MIRA grants. Early-Stage Investigators (ESIs) should not apply to this FOA but should instead use the ESI MIRA FOA.
The Institute will also work to ensure that it maintains a broad and diverse research portfolio in terms of scientific areas, approaches, regions, institutions, and individuals. Such diversity will optimize returns on the Institute’s investments by maximizing the ideas explored and the chances for important breakthroughs.
The NIGMS MIRA differs from other institutes' R35 awards in that MIRA is not a grant designed to support a small number of investigators; instead the Institute intends to have at least 60% of the R01-equivalent pool eventually be MIRAs as stated in the Institute's strategic plan.
NIGMS recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. See, Notice of NIH's Interest in Diversity, NOT-OD-20-031.
To support the best science, NIGMS encourages inclusivity in research. Examples of structures that promote diverse perspectives include, but are not limited to:
-
Transdisciplinary research projects and collaborations among investigators from different fields
-
Engagement from different types of institutions and organizations (e.g., research-intensive, undergraduate-focused, minority-serving, community-based).
-
Individual applications and partnerships that enhance geographic and regional heterogeneity.
-
Investigators and teams composed of researchers at different career stages.
- Participation of individuals from diverse backgrounds, including groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women.
-
Project-based opportunities to enhance the research environment to benefit early- and mid-career investigators.?
Overview of the MIRA
An NIGMS MIRA is intended to provide support for the NIGMS-related research program in an investigator’s laboratory. NIGMS supports research on basic biological processes as well as translational and clinical research in certain areas. In addition to research designed to answer scientific questions and generate new ideas and hypotheses, the development of technology and computational approaches are supported. Within the scope of the MIRA, investigators will have the freedom to explore new avenues of inquiry that arise during the course of their research, as long as they remain within the mission of NIGMS. Work involving the addition of human subjects, vertebrate animals, stem cells, select agents, or a new foreign component would require prior approval by NIGMS staff according to existing policies and procedures.
In comparison to R01 funding of NIGMS investigators, MIRA benefits include:
- A longer grant period - five-year awards rather than the current NIGMS median of four years;
- More flexibility to pursue new ideas and opportunities as they arise during the course of research because the award is not tied to specific aims or predicated on completing specific, pre-defined projects;
- Increased stability of funding through longer-term commitments of support, improved success rates, and the possibility of more graduated, rather than all-or-none, funding decisions for R35 renewals;
- A reduction in administrative burden associated with managing multiple grants;
- A reduction in required application writing.
MIRA may not be the best mechanism to support all kinds of research, even though the research may be within the NIGMS mission. Because the MIRA is expected to support the research program of an independent investigator’s laboratory, PDs/PIs may find other grant programs better suited to research requiring financial support of collaborators and subcontractors.
Research involving human subjects is permitted in the MIRA program. Clinical research must be completely within the context of the research areas supported by NIGMS, which include several specific clinical areas: anesthesiology, perioperative pain, clinical pharmacology, sepsis, injury and critical illness, wound healing, innate immunity and inflammation. Clinical research that involves recruitment of human subjects at more than one site or the substantial financial support of multiple collaborators and subcontractors is not allowed, because these fixed commitments are not consistent with the highly flexible nature of the MIRA program. Mechanistic clinical trials are permitted in MIRA when the mechanistic study is an essential part of the research program. Clinical trials that are designed to test safety and efficacy of interventions (Phase I, Phase II, Phase III) for the purpose of future clinical treatment and/or regulatory approval are not permitted in MIRA. Studies that propose clinical dissemination and implementation research, comparative effectiveness research, and/or pragmatic clinical trials are also not permitted.
Potential applicants are strongly encouraged to confer with the program official managing their qualifying award(s) or relevant research portfolio(s), and if there are further questions, with the NIGMS Scientific/Research staff (in Section VII. Agency Contacts of this FOA) before submitting a MIRA application. NIGMS will not fund applications that contain research within the missions of other Institutes and Centers at NIH or other federal agencies.
Also, because a MIRA is designed to provide support for a laboratory's research relevant to the mission of NIGMS, it is deemed to have overlap with most other research grant applications within the NIGMS mission.
Overlap During Peer Review
A PD/PI may not have a MIRA application and another research grant application (e.g., R01, R15, R21) within NIGMS mission pending review* at the same time, with the following exceptions:
- Grants supporting resources for the research community
- Collaborative Program Grant for Multidisciplinary Teams (RM1) grants**;
- Biomedical Technology Development and Dissemination (RM1) grants***;
- Sepsis Human Biospecimen Collections (R21/R33) Phased Innovation Awards****;
- Contracts;
- Grants supporting training, workforce development, or diversity building activities;
- Grants supporting multi-site clinical research, both clinical trials and observational studies, with costs for patient recruitment, protocol-related expenses, and/or community resource activities (e.g., specimen banking, dissemination);
- INBRE (P20), COBRE (P20/P30), IDeA-CTRs (U54), SEPA, or NARCH;
- SBIR/STTR grants;
- Conference grants.
Resolving Overlap with Other NIGMS Research Grants During the Award Process
Investigators receiving a MIRA will be required to relinquish funding from other NIGMS research grants, including the following scenarios:
- Investigators who receive support from NIGMS research grants of other investigators as collaborators and subcontractors on R01s will no longer be permitted to receive funds from those sources.
- Investigators who receive research funds as project leaders or multiple PD/PIs on NIGMS multi-component and complex (e.g., Collaborative Program Grant for Multidisciplinary Teams (RM1)) grants will have their MIRA award level adjusted to remove any overlap between their MIRA and their multi-component or complex grant. The MIRA PD/PI will be required to relinquish funding from the multi-component or complex grant at the end of its competitive segment. NIGMS continues to encourage collaborative and interdisciplinary research when it is appropriate, and individual MIRA grantees are free to collaborate with one another or with other investigators using funds from their individual MIRA to support their contributions to the team's research.
- Investigators with K awards from NIGMS will be required to relinquish the K award prior to the start date of the MIRA. Investigators with K awards from another NIH institute may receive an NIGMS MIRA but will be required to adjust their person-months effort on those awards to be smaller than the person-months effort committed to MIRA.
NIGMS will establish an orderly process to MIRA funding when reductions in other commitments are required. Details of how these changes may be accomplished are covered in Frequently Asked Questions on the MIRA web page.
The budget of a MIRA will be determined by NIGMS staff, based upon the NIGMS funding history of the PD/PI, the recommendations of the initial review group and the National Advisory General Medical Sciences Council, and the expected productivity and impact of the program of research. NIGMS' Special Council Review policy for applications that result in over $1,500,000 annual total costs from all sources of research support being awarded to a PD/PI will apply to MIRAs.
Well-funded grantees (having more than $400,000 in direct costs from NIGMS research grants) applying for new MIRAs will generally receive budgets about 12% lower than their previous average NIGMS research funding levels (as determined by NIGMS staff). MIRA budgets for New Investigators will generally be $250,000 in annual direct costs. Note that the Institute does not intend to use a similar blanket policy when setting budgets for MIRA renewals.
The funding levels for each MIRA renewal will be independently determined based on a variety of considerations, including the results of peer review, the PI’s other support and commitments, and the Institute’s scientific priorities and available budget. Overall, we expect most budgets for MIRA renewals to be similar to what they were in the previous funding period, although some grants will have increased or decreased budgets. For more information, see this Feedback Loop Post.
Applying for Subsequent Awards after Receiving a MIRA
NIGMS will not accept applications from MIRA grantees for awards that would begin prior to the end date of the MIRA, with the exceptions listed above.
Additionally, NIGMS will not accept assignment of an NIH Director's Transformative Research Award (TRA) R01 or NIH Director's Pioneer Award (DP1) application if the PD/PI has a MIRA. By virtue of assignment to NIGMS, the proposed research falls within the mission of NIGMS and would overlap with the MIRA.
Supplements to MIRAs: MIRAs will be eligible for Research Supplements to Promote Diversity in Health-Related Research, for Research Supplement to Promote Re-Entry into Biomedical and Behavioral Research Careers, and for Administrative Supplements for Equipment Purchases. Other supplements offered by NIGMS may also be made available to MIRA grantees, depending on the intention and constraints of the particular supplement program.
Renewals: Because of the Institute's commitment to the MIRA program and the fact that there will be fewer applications as a result of the consolidation of separate research projects, NIGMS anticipates a higher success rate for R35 renewal applications than is the case for R01s. If an application for renewal of the MIRA is unsuccessful, the grant will terminate at the end of its approved project period. Although a resubmission will not be accepted, a PD/PI may submit a new MIRA application when the PD/PI remains eligible.
Notes:
*Applications are defined as pending review until a summary statement is issued.
** MIRA applicants and recipients can participate as a PD/PI on a Collaborative Program Grant for Multidisciplinary Teams (RM1) as part of the 51% effort required by the MIRA but may not receive additional funds from this RM1.
*** For the Biomedical Technology Development and Dissemination (BTDD) grants, the PD/PI must maintain 51% research effort toward their MIRA, and 3 person months' effort toward the BTDD. The BTDD award can only provide support in a MIRA PD/PI's laboratory for late-stage technology development and dissemination efforts.
****For the Sepsis Human Biospecimen Collections (R21/R33) Phased Innovation Awards, if a New Investigator is issued the R33 portion of the phased award prior to the MIRA, they are no longer eligible as a New Investigator to receive the MIRA.
See Section VIII. Other Information for award authorities and regulations.
Grant: A support mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.
Renewal
The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types. Only those application types listed here are allowed for this FOA.
Optional: Accepting applications that either propose or do not propose clinical trial(s).
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Applications from investigators with existing NIGMS research grants may request no more than $750,000 direct costs per year. Investigators should request well-justified actual costs for their research program and to recognize that efficient use of funds is an expectation of the MIRA program and is considered during the review process and in making funding decisions. In general, awards will be commensurate with the investigator’s average total NIGMS research funding over the past few years.
For new applications from PDs/PIs previously funded through NIGMS R01-equivalents, well-justified increases over previous funding levels will be considered for PDs/PIs previously supported by modest budgets (<$250,000 in annual direct costs ), while modest reductions (~12%, on average) should be anticipated for well-funded PDs/PIs ($400,000 or more in annual direct costs from NIGMS). The MIRA budget will generally not be at the level of an NIH Transformative Research Award and will be significantly reduced from NIH Director's Pioneer Award (DP1) level.
MIRA budgets for New Investigators will generally be $250,000 in annual direct costs.
For MIRA renewal applications, NIGMS expects that the award level will be flexible, and a budget increase is possible when well-justified and funds are available. Meritorious applications that are not among the highest priority for funding may be awarded at reduced budget levels.
Other than years when equipment is requested, it is expected that the annual direct costs will remain constant in all years of an award period.
Applications may request a maximum project period of five years.
NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this FOA.
1. Eligible Applicants
Higher Education Institutions
- Public/State Controlled Institutions of Higher Education
- Private Institutions of Higher Education
The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:
- Hispanic-serving Institutions
- Historically Black Colleges and Universities (HBCUs)
- Tribally Controlled Colleges and Universities (TCCUs)
- Alaska Native and Native Hawaiian Serving Institutions
- Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)
Nonprofits Other Than Institutions of Higher Education
- Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
- Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)
For-Profit Organizations
- Small Businesses
- For-Profit Organizations (Other than Small Businesses)
Local Governments
- State Governments
- County Governments
- City or Township Governments
- Special District Governments
- Indian/Native American Tribal Governments (Federally Recognized)
- Indian/Native American Tribal Governments (Other than Federally Recognized)
Federal Government
- Eligible Agencies of the Federal Government
- U.S. Territory or Possession
Other
- Independent School Districts
- Public Housing Authorities/Indian Housing Authorities
- Native American Tribal Organizations (other than Federally recognized tribal governments)
- Faith-based or Community-based Organizations
- Regional Organizations
Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Applicant organizations
Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.
- System for Award Management (SAM) Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.
- NATO Commercial and Government Entity (NCAGE) Code Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM.
- Unique Entity Identifier (UEI)- A UEI is issued as part of the SAM.gov registration process. SAM registrations prior to fall 2021 were updated to include a UEI. For applications due on or after January 25, 2022, the UEI must be provided on the application forms (e.g., FORMS-G); the same UEI must be used for all registrations, as well as on the grant application.
- eRA Commons - Once the unique organization identifier (UEI after April 2022) is established, organizations can register with eRA Commons in tandem with completing their full SAM and Grants.gov registrations; all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
- Grants.gov Applicants must have an active SAM registration in order to complete the Grants.gov registration.
Program Directors/Principal Investigators (PD(s)/PI(s))
All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.
Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. See, Reminder: Notice of NIH's Encouragement of Applications Supporting Individuals from Underrepresented Ethnic and Racial Groups as well as Individuals with Disabilities, NOT-OD-22-019.
Subject to the eligibility criteria below, individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Women, individuals from underrepresented racial and ethnic groups, from disadvantaged backgrounds, or with disabilities are always encouraged to apply for NIH support.
PDs/PIs whose only NIGMS research grant(s) is a multi-PD/PI grant(s) are not eligible to apply for a MIRA.
For this FOA, PDs/PIs with a funded NIGMS R35 are eligible to submit a renewal MIRA application before the end of their eligibility time window. Successful renewal applications will generally be awarded in the fiscal year of Council review, and the current MIRA will be terminated upon the issuance of the new MIRA award. If a renewal MIRA application is unsuccessful, a new MIRA application may be submitted as long as the PD/PI remains eligible. The eligibility for investigators funded with a MIRA extends to the end of the second fiscal year following the one in which the funded MIRA was originally set to expire.
For this FOA, PDs/PIs with at least one NIGMS single-PD/PI R01-equivalent award (defined here as R01, NRMN U01, R37, DP1, DP2, and SC1) are eligible to submit a new MIRA application(s) before the end of their eligibility time window. Successful MIRA applications will be awarded in the fiscal year of Council review. If a pending MIRA application is unsuccessful, another new MIRA application(s) may be submitted as long as the PD/PI remains eligible. The eligibility for investigators funded with at least one single-PD/PI NIGMS R01 or equivalent award extends to the end of the fiscal year following the one in which the funded single-PD/PI R01 or equivalent award was originally set to expire.
NIH will consider requests to extend the eligibility to apply for a MIRA for life events (e.g., childbirth or adoption, military service, health-related issues, natural disasters) that impact research progress during the eligibility window. Applicants seeking an extension of their eligibility status must contact a Scientific/Research Contact at least 8 weeks before submitting the application.
For this FOA, New Investigators proposing research within the scientific mission of NIGMS are eligible to apply for a MIRA if the PD/PI is not a project leader on any multi-component awards from NIH, except for research project leaders and pilot project leaders in NIGMS COBRE, NIGMS IDeA-CTR or NIGMS NARCH awards who are eligible to apply. Potential applicants are strongly encouraged to contact NIGMS program staff to discuss the relevance of their research program to the NIGMS mission before submitting a MIRA application. Applications that fall outside of the NIGMS mission will be withdrawn prior to review.
ESIs should apply for a MIRA only through the MIRA FOA for ESIs.
This FOA does not allow resubmissions, although a new application can be submitted after an unsuccessful attempt as long as the PD/PI remains eligible, as defined above.
The PD/PI is required to devote at least 51% of the PD/PI's total research effort to this award. The total research effort should include the PD/PI's combined research effort at all institutions where the PD/PI holds an appointment, should be expressed in person-months, and should not include time expended toward teaching, administration not directly related to the PD's/PI's research, and/or clinical duties. NIGMS staff will verify the MIRA research effort requirement is met by using the Other Support documentation and will exclude support for which the purpose is education, training or enhancing workforce diversity.
All current NIGMS research grants except those listed in Section I will be terminated upon the issuance of the new MIRA grants. Investigators who receive funds as project leaders on multi-component NIGMS grants (i.e., P50 or RM1) will have their MIRA award level adjusted to remove any overlap between their MIRA and their multi-component grant. The MIRA PD/PI will be required to relinquish their involvement in the multi-component grant at the end of its competitive segment.
2. Cost Sharing
This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
3. Additional Information on Eligibility
Number of Applications
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.
The NIH will not accept duplicate or highly overlapping applications under review at the same time, per 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:
- A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
- A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
- An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications)
Because MIRAs are designed to provide support for a laboratory's research relevant to the mission of NIGMS, it is deemed to have overlap with any other pending research grant applications within the scientific mission of NIGMS. Therefore, NIGMS will not accept a MIRA application from an investigator who is the PD/PI of another overlapping application under review, except as mentioned under Section I. Conversely, NIGMS will not accept any other applications from an investigator who has a MIRA application under review, except as mentioned under Section I.
1. Requesting an Application Package
The application forms package specific to this opportunity must be accessed through ASSIST, Grants.gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.gov Workspace are available in Part 1 of this FOA. See your administrative office for instructions if you plan to use an institutional system-to-system solution.
2. Content and Form of Application Submission
It is critical that applicants follow the instructions in the Research (R) Instructions in the SF424 (R&R) Application Guide except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed.
Note: Effective for due dates on or after January 25, 2023, the Data Management and Sharing (DMS) Plan will be attached in the Other Plan(s) attachment in FORMS-H and subsequent application forms packages. For due dates on or before January 24, 2023, the Data Sharing Plan and Genomic Data Sharing Plan GDS) will continue to be attached in the Resource Sharing Plan attachment in FORMS-G application forms packages.
The following section supplements the instructions found in the SF424 (R&R) Application Guide and should be used for preparing an application to this FOA.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
Project Summary/Abstract: For this FOA, use the abstract to provide an overview of research in the laboratory, the goals for the next five years, and the overall vision of the research program. Do not include specific aims or use any similar designation in the abstract. This abstract should serve both the needs of the public and the needs of the reviewers for an introduction to the research plan.
Other Attachments: The application must include the following attachment.
Plan for Enhancing Diverse Perspectives (PEDP) (1-page maximum): All applications must include a summary of strategies to advance the scientific and technical merit of the proposed project through expanded inclusivity. The PEDP should provide a holistic and integrated view of how enhancing diverse perspectives is viewed and supported throughout the application and can incorporate elements with relevance to any review criteria (significance, investigator(s), innovation, approach, and environment) as appropriate. Where possible, applicant(s) should align their description with these required elements within the research strategy section. The PEDP will vary depending on the scientific goals, expertise required, the environment and performance site(s), as well as how the project goals are structured. The PEDP should include a timeline and milestones for relevant components that will be considered as part of the review. Examples of items that advance inclusivity in research and may be part of the PEDP can include, but are not limited to:
- Discussion of engagement with different types of institutions and organizations (e.g., research-intensive, undergraduate-focused, minority-serving, community-based).
- Description of any planned partnerships that may enhance geographic and regional diversity.
- Plan to enhance recruiting of women and individuals from groups traditionally under-represented in the biomedical, behavioral, and clinical research workforce.
- Proposed monitoring activities to identify and measure PEDP progress benchmarks.
- Plan to utilize the project infrastructure (i.e., research and structure) to support career-enhancing research opportunities for diverse junior, early- and mid-career researchers.
- Description of any training and/or mentoring opportunities available to encourage participation of students, postdoctoral researchers and co-investigators from diverse backgrounds.
- Plan to develop transdisciplinary collaboration(s) that require unique expertise and/or solicit diverse perspectives to address research question(s).
- Publication plan that enumerates planned manuscripts and proposed lead authorship.
- Outreach and planned engagement activities to enhance recruitment of individuals from diverse groups as research participants including those from under-represented backgrounds.
If this attachment is not included, the application will be considered incomplete and will not be reviewed.
All instructions in the SF424 (R&R) Application Guide must be followed.
Biographical Sketches: A biosketch should only be provided for the PD/PI and in rare cases, for collaborator(s) receiving financial support from the MIRA.
Personal Statement: The Personal Statement should be tailored to the unique attributes and requirements of MIRA. Include descriptions of significant service to the scientific community that are beyond normal mentoring and committee duties expected at the PD's/PI's institution.
Contributions to Science: This section of the biosketch should emphasize contributions over the past five years. Because this FOA is for PDs/PIs with funded R35 or R01-equivalent research funding from NIGMS or for New Investigators seeking funding from NIGMS, applicants are encouraged to clearly state contributions that are within the scientific mission of NIGMS, and whenever applicable, have resulted from NIGMS support. Cite all sources of support as originally acknowledged in the publications for each paper listed.
Applicants may include a link to your My Bibliography complete list of publications.
Do not include figures or preliminary data.
Current & Pending Support: This attachment is required. For the PD/PI only, use the SF424 R&R Current and Pending Support instructions as modified here. List ongoing and completed research projects from the past three years as well as pending application(s). Briefly indicate the overall goals of the projects and your responsibilities. Explain if there is any overlap with other awards and pending applications. List Total Costs for the Entire Project Period, Annual Direct Costs allocated to the MIRA PD's/PI's laboratory, and subawards to collaborator(s)' laboratories. List the PD's/PI's effort on each grant in person-months.
All sources of support including foreign support should be reported. List NIGMS grants first, followed by other NIH grants, followed by other sources of support.
R&R Budget
All instructions in the SF424 (R&R) Application Guide must be followed.
Itemized budget information is not required and will not be accepted. Instead, a total requested direct cost amount for each budget period, including requests for equipment purchase, is required. Other than years when equipment is requested, it is expected that the annual direct costs will remain constant in all years.
All instructions in the SF424 (R&R) Application Guide must be followed except as detailed below. While a 10-year R&R Detailed Budget form is provided in the application package, applicants may not request more than 5 years of support.
In order to allow submission of a budget request without filling out detailed yearly budgets, some basic information must be completed in order for NIH to successfully process the budget form. For each budget period:
1. Select the appropriate Budget Type.
2. Provide the Budget Period Start Date and End Date.
3. Section A: Senior/Key Persons Provide an entry for the PD/PI, including the appropriate level of effort, and enter $0 for Requested Salary and $0 for Fringe Benefits. Entering $0 does not imply that the PD/PI will not receive any salary or fringe benefit support from the grant.
4. In Section C: Enter budget request for equipment. Provide complete justification using the Budget Justification.
5. In Section F: Other Direct Costs Add a line item titled Requested Direct Costs and provide the total request for that budget period (up to $750,000). If equipment is requested in Section C, do not add the equipment budget in Section F. Other than when equipment is requested it is expected that the total annual direct costs requested will remain constant in future years.
6. In Section H: Enter your institutional "indirect cost type," "indirect cost rate," "indirect cost base" and "funds requested."
Budget Justification: The following budget categories must be justified, where applicable: equipment, and consortium/subaward costs. For MIRA renewal applications, justify any increase in funding requested over the previous project period. For applications for new MIRA grants, justify any requested increase in support relative to NIGMS research support over the previous three years. New Investigators should request a maximum of $250,000 in direct costs, not including equipment costs.
Use the Budget Justification to provide the additional information requested in each budget category identified above only. Equipment quote(s) may be included here.
Data Management and Sharing Costs: NIGMS expectation is that most NIGMS grantees will not need to significantly change their data management and sharing practices and thus additional costs, if any, will be modest.
Justification for any requested Data Management and Sharing costs should be clearly labeled as "Data Management and Sharing Justification" and include any requested direct costs dollar amount. If no costs are requested for DMS, state 0 for the requested dollar amount. Follow instructions in the SF424 Application Guide for the Data Management and Sharing Justification.
Consortium Justification: Consortium/Contractual Arrangements are not anticipated in most cases and must be extremely well justified. A letter from the subcontract PD/PI should be included making it clear why he/she cannot participate in collaborative research with the PD/PI without support from the MIRA. NIGMS will accept MIRA applications with foreign collaborations but will only provide funding for a foreign consortium arrangement when the collaboration is essential to the PD's/PI's research program and represents a unique scientific opportunity that cannot be supported by the collaborator without MIRA funds.
Provide an estimate of total consortium/subaward costs (direct costs plus indirect [F&A] costs) for each budget period, rounded to the nearest $1,000.
List the individuals/organizations with whom consortium or contractual arrangements have been made and indicate whether the collaborating institution is foreign or domestic.
F&A base: Also use the Budget Justification to explain any exclusions applied to the F&A base calculation.
If none of the above apply, state "Not Applicable."
Do not complete the R&R Subaward form. All budget information should be provided on the R&R Budget form.
All instructions in the SF424 (R&R) Application Guide must be followed.
Other Plan(s):
Note: Effective for due dates on or after January 25, 2023, the Data Management and Sharing Plan will be attached in the Other Plan(s) attachment in FORMS-H and subsequent application forms packages. For due dates on or before January 24, 2023, the Data Sharing Plan and Genomic Data Sharing Plan GDS) will continue to be attached in the Resource Sharing Plan attachment in FORMS-G application forms packages.
All applicants planning research (funded or conducted in whole or in part by NIH) that results in the generation of scientific data are required to comply with the instructions for the Data Management and Sharing Plan. All applications, regardless of the amount of direct costs requested for any one year, must address a Data Management and Sharing Plan.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:
Specific Aims: Do not submit a Specific Aims page or identify specific aims or use any similar designation in the Research Strategy.
Research Strategy: Upload the Research Strategy as a single attachment. MIRA applications should not use the typical R01 application headings of Significance, Innovation, and Approach. This section should contain the following information: 1) Background on the area(s) of research and key gaps in our understanding or important challenges to be addressed. 2) Recent Progress by the PD/PI which focuses on the past five years. Do not repeat material adequately covered in the Biosketch. 3) Overview of Future Research Plans. This should be a description of the key questions or challenges the PD/PI plans to address and the general strategies that might be used to approach them. The focus should be mainly on the importance of the questions or challenges. A detailed experimental plan should not be provided. Although the proposed direction of the PD's/PI’s scientific program will be considered in review, if new opportunities or directions within the mission of NIGMS arise during the course of the research, the PD/PI will have the flexibility to change course and pursue them.
Given that the MIRA is intended to enable consolidation of NIGMS support for multiple projects that may be disparate, there is no obligation to develop a single unifying theme. Applicants should directly address the rationale underlying the balance of effort and the resources dedicated to each activity, and how the activities are distinct or complementary.
The research strategy should address the requirements of the NIH policy on rigor and transparency in research as detailed in NOT-OD-18-228. This section should also address requirements related to sex as a biological variable as detailed in NOT-OD-15-102.
Progress Report Publication List: For renewal MIRA applications, follow the instructions in the SF424 Application Guide to prepare the progress report publication list. In addition, for each publication identify all funding sources acknowledged, and for those publications with multiple funding sources, identify which aspects were supported by the MIRA.
Letters of Support: Letters of support from collaborators should be limited to 1 page, may not include attached Biographical Sketches, and must not circumvent page limitations by including figures and data.
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide.
The following modifications also apply:
- All applications, regardless of the amount of direct costs requested for any one year, should include both a Resource and a Data Sharing Plan.
When involving human subjects research, clinical research, and/or NIH-defined clinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:
If you answered Yes to the question Are Human Subjects Involved? on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or Delayed Onset Study record.
Study Record: PHS Human Subjects and Clinical Trials Information
All instructions in the SF424 (R&R) Application Guide must be followed.
Delayed Onset Study
Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start).All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
3. Unique Entity Identifier and System for Award Management (SAM)
See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov
Part I. Overview Information contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.
Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Policy on Late Application Submission.
Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.
Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.
5. Intergovernmental Review (E.O. 12372)
This initiative is not subject to intergovernmental review.
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-award costs are allowable only as described in the NIH Grants Policy Statement.
For this FOA:
- A permanent change of PD/PI will not be allowed under the MIRA. A temporary change may be allowed with NIGMS' prior approval under circumstances such as sabbatical leave, medical conditions, disability, or personal or family situations. In case of changes in employment of the PD/PI (e.g., accepting an appointment at another institution, while retaining an appointment at the institution which received the MIRA award), the PD/PI is required to maintain his/her commitment to MIRA as originally reviewed and approved. The situation will be evaluated on a case by case basis and the MIRA could be terminated if continued support is not warranted.
- Transfer of a MIRA to a foreign institution will not be allowed. Addition of a foreign component, including a significant new foreign collaboration, requires NIGMS' prior approval; however, MIRA funds may be used to support a subcontract at a foreign institution, but only if the collaboration is essential to the PD's/PI's research program, represents a unique scientific opportunity and cannot be supported by the collaborator without MIRA funds.
- The MIRA will replace all current NIGMS research funding of the laboratory with the exception of those listed above in Section I. Institutions will be required to relinquish their interests in current NIGMS-funded research grants and withdraw pending applications where the MIRA investigator is listed as the PD/PI or multi-PD/PI.
- The PD/PI of a MIRA cannot receive funds from other NIGMS grants (e.g., as a sub-project leader or as the recipient of a sub-contract), excepting those listed in Section I.
- NIGMS will not consider funding future individual PD/PI or multiple PD/PI research grant applications from a MIRA investigator during the MIRA funded project period, except for applications included under the list of exempted awards in Section I. Thus, NIGMS will not accept applications for grants not on the list of exempted awards from MIRA PDs/PIs unless the earliest start date of the grant is after the end date of the MIRA grant.
- Because most institutions expect some commitment from investigators to administrative, teaching and/or clinical duties, any salary support for the PD/PI charged to the grant should generally be less than 51% of the PD/PI's annual salary and should in no case be more than the actual research effort the PD/PI will devote to the grant.
Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.
Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.
For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply Application Guide. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.
Important reminders:
All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this FOA for information on registration requirements.
The applicant organization must ensure that the unique entity identifier (UEI) provided on the application is the same number used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.
See more tips for avoiding common errors.
Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and the National Institute of General Medical Sciences. Applications that are incomplete or non-compliant, or that do not fall within the NIGMS mission, will not be reviewed.
Applicants are required to follow the instructions for post-submission materials, as described in the policy.
1. Criteria
Note: Effective for due dates on or after January 25, 2023, the Data Sharing Plan and Genomic Data Sharing Plan (GDS) as part of the Resource Sharing Plan will not be evaluated at time of review.
Only the review criteria described below will be considered in the review process. Applications submitted to the NIH in support of the NIH mission are evaluated for scientific and technical merit through the NIH peer review system.
For this particular announcement, note the following:
The goal of the MIRA program is to provide support for a laboratory’s research program that is within the NIGMS mission, and to give investigators relative freedom in pursuing their research goals. For this FOA, applicants are expected to provide an overview of the research program/scientific questions they currently plan to address and a general description of possible strategies. Experimental details are not expected. Given that a MIRA is intended to administratively consolidate projects that may be scientifically disparate, there is no obligation for the PD/PI to present a single unifying theme.
A proposed Clinical Trial application may include study design, methods, and intervention that are not by themselves innovative but address important questions or unmet needs. Additionally, the results of the clinical trial may indicate that further clinical development of the intervention is unwarranted or lead to new avenues of scientific investigation.
Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the research program to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the proposed research program).
Review Criteria
Reviewers will consider each of the review criteria below in the determination of scientific merit but will not provide a separate score for individual criterion. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a research program that by its nature is not innovative may be essential to advance a field.
Significance
Does the research program address an important problem or a critical barrier to progress in the field? Is the prior research that serves as the key support for the proposed research rigorous? If the goals of the research are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved?
Specific to this FOA:
Are the theme and/or topics of the research program substantive and appropriate for long-term pursuit? Is the proposed research program appropriate in scope and ambition to address the scientific questions posed? To what extent do the efforts described in the Plan for Enhancing Diverse Perspectives further the significance of the project?
In addition, for applications involving clinical trials
Are the scientific rationale and need for a clinical trial to test the proposed hypothesis or intervention well supported by preliminary data, clinical and/or preclinical studies, or information in the literature or knowledge of biological mechanisms? For trials focusing on clinical or public health endpoints, is this clinical trial necessary for testing the safety, efficacy or effectiveness of an intervention that could lead to a change in clinical practice, community behaviors or health care policy? For trials focusing on mechanistic, behavioral, physiological, biochemical, or other biomedical endpoints, is this trial needed to advance scientific understanding?
Investigator(s)
Are the PD(s)/PI(s), collaborators, and other researchers well suited to the research program? Has the PD/PI demonstrated a record of accomplishments over the past five years that has advanced their field(s)? If the research is collaborative, do the investigators have complementary and integrated expertise?
Specific to this FOA:
Is the PD/PI clearly the intellectual driver of the proposed research program? Has the PD/PI shown evidence of being creative and adaptable, able to recognize new opportunities and explore new areas of scientific inquiry, and open to the use of new systems and strategies, as appropriate for the proposed research program? Does the PD/PI have a record of conducting and reporting rigorous, reproducible, transparent, and cost-effective research? Does the PD/PI have a record of significant service to the scientific community? Are the investigator's productivity and impact commensurate with their level of funding and career stage?
To what extent will the efforts described in the Plan for Enhancing Diverse Perspectives strengthen and enhance the expertise required for the project?
In addition, for applications involving clinical trials
With regard to the proposed leadership for the project, do the PD/PI(s) and key personnel have the expertise, experience, and ability to organize, manage and implement the proposed clinical trial and meet milestones and timelines? Do they have appropriate expertise in study coordination, data management and statistics? For a multicenter trial, is the organizational structure appropriate and does the application identify a core of potential center investigators and staffing for a coordinating center?
Innovation
Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?
Specific to this FOA:
Will creative strategies be employed as needed and appropriate to address the research questions posed? Is there evidence that the freedom and flexibility of the MIRA will lead to innovation? To what extent will the efforts described in the Plan for Enhancing Diverse Perspectives meaningfully contribute to innovation?
In addition, for applications involving clinical trials
Does the design/research plan include innovative elements, as appropriate, that enhance its sensitivity, potential for information or potential to advance scientific knowledge or clinical practice?
Approach
Is the overall strategy well-reasoned and appropriate to accomplish the goals of the research program? Have the investigators included plans to address weaknesses in the rigor of prior research that serves as the key support for the proposed research? Has the PD/PI presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the research program is in the early stages of development, will the strategy establish feasibility, and will particularly risky aspects be managed? Has the PD/PI presented adequate plans to address relevant biological variables, such as sex?
If the proposed research involves human subjects and/or NIH-defined clinical research, are the plans to address: (1) the protection of human subjects from research risks, and (2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of individuals of all ages (including children and older adults), justified?
Specific to this FOA:For this particular announcement, note the following: Is there a logical plan for sustained progress across a research program for the award period? Is there evidence that the research program will evolve appropriately as the work is performed? Are the timeline and milestonesassociated with the Plan for Enhancing Diverse Perspectives well-developed and feasible?
In addition, for applications involving clinical trials
Does the application adequately address the following, if applicable
Study Design
Is the study design justified and appropriate to address primary and secondary outcome variable(s)/endpoints that will be clear, informative and relevant to the hypothesis being tested? Is the scientific rationale/premise of the study based on previously well-designed preclinical and/or clinical research? Given the methods used to assign participants and deliver interventions, is the study design adequately powered to answer the research question(s), test the proposed hypothesis/hypotheses, and provide interpretable results? Is the trial appropriately designed to conduct the research efficiently? Are the study populations (size, gender, age, demographic group), proposed intervention arms/dose, and duration of the trial, appropriate and well justified?
Are potential ethical issues adequately addressed? Is the process for obtaining informed consent or assent appropriate? Is the eligible population available? Are the plans for recruitment outreach, enrollment, retention, handling dropouts, missed visits, and losses to follow-up appropriate to ensure robust data collection? Are the planned recruitment timelines feasible and is the plan to monitor accrual adequate? Has the need for randomization (or not), masking (if appropriate), controls, and inclusion/exclusion criteria been addressed? Are differences addressed, if applicable, in the intervention effect due to sex/gender and race/ethnicity?
Are the plans to standardize, assure quality of, and monitor adherence to, the trial protocol and data collection or distribution guidelines appropriate? Is there a plan to obtain required study agent(s)? Does the application propose to use existing available resources, as applicable?
Data Management and Statistical Analysis
Are planned analyses and statistical approach appropriate for the proposed study design and methods used to assign participants and deliver interventions? Are the procedures for data management and quality control of data adequate at clinical site(s) or at center laboratories, as applicable? Have the methods for standardization of procedures for data management to assess the effect of the intervention and quality control been addressed? Is there a plan to complete data analysis within the proposed period of the award?
Environment
Are the institutional support, equipment and other resources available to the investigators adequate for the research program proposed? Will the research program benefit from unique features of the scientific environment, subject populations, or collaborative arrangements? To what extent will features of the environment described in the Plan for Enhancing Diverse Perspectives (e.g., collaborative arrangements, geographic diversity, institutional support) contribute to the success of the project?
In addition, for applications involving clinical trials
If proposed, are the administrative, data coordinating, enrollment and laboratory/testing centers, appropriate for the trial proposed?
Does the application adequately address the capability and ability to conduct the trial at the proposed site(s) or centers? Are the plans to add or drop enrollment centers, as needed, appropriate?
If international site(s) is/are proposed, does the application adequately address the complexity of executing the clinical trial?
If multi-sites/centers, is there evidence of the ability of the individual site or center to: (1) enroll the proposed numbers; (2) adhere to the protocol; (3) collect and transmit data in an accurate and timely fashion; and, (4) operate within the proposed organizational structure?
Additional Review Criteria
As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.
Study Timeline
Specific to applications involving clinical trials
Is the study timeline described in detail, taking into account start-up activities, the anticipated rate of enrollment, and planned follow-up assessment? Is the projected timeline feasible and well justified? Does the project incorporate efficiencies and utilize existing resources (e.g., CTSAs, practice-based research networks, electronic medical records, administrative database, or patient registries) to increase the efficiency of participant enrollment and data collection, as appropriate?
Are potential challenges and corresponding solutions discussed (e.g., strategies that can be implemented in the event of enrollment shortfalls)?
Protections for Human Subjects
For research that involves human subjects but does not involve one of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or more of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.
Inclusion of Women, Minorities, and Individuals Across the Lifespan
When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of individuals of all ages (including children and older adults) to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.
Vertebrate Animals
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
Biohazards
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
Resubmissions
Not Applicable
Renewals
For renewals, the committee will consider the progress made in the last MIRA funding period. For renewals of previous ESI MIRAs, has the PD/PI established a research program with the potential for continued growth and enhanced scientific impact? For renewals of established investigator MIRAs, has the PD/PI maintained a productive research program with strong evidence of impactful contribution to the field and recognition of new opportunities and directions?
Revisions
Not Applicable
Note: Effective for due dates on or after January 25, 2023, the Data Sharing Plan and Genomic Data Sharing Plan (GDS) as part of the Resource Sharing Plan will not be evaluated at time of review.
As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.
Applications from Foreign Organizations
Not Applicable
Select Agent Research
Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Resource Sharing Plans
Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: (1) Data Sharing Plan; (2) Sharing Model Organisms; and (3) Genomic Data Sharing Plan (GDS).
Authentication of Key Biological and/or Chemical Resources:
For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.
Budget and Period of Support
Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable. Reviewers will rate the budget request as either (1) appropriate, or (2) excessive in relation to the scope and predicted impact of proposed research program.
2. Review and Selection Process
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by the Center for Scientific Review, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.
As part of the scientific peer review, all applications will receive a written critique.
Applications may undergo a selection process in which only those applications deemed to have the highest scientific and technical merit will be discussed and assigned an overall impact score.
All applications will be assigned to NIGMS. Following initial peer review, scored applications will receive a second level of review by the National Advisory General Medical Sciences Council. Applications will compete for available funds with all other recommended applications.
The following will be considered in making funding decisions:
- Scientific and technical merit of the proposed research as determined by scientific peer review.
- Availability of funds.
- Relevance of the proposed research to NIGMS' priorities.
- Contributions to portfolio breadth and diversity.
- Other funding support to the PD/PI.
3. Anticipated Announcement and Award Dates
After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons. Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.
Information regarding the disposition of applications is available in the NIH Grants Policy Statement.
1. Award Notices
If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the NIH Grants Policy Statement and this FOA. Additionally, a signed letter from the institution's Authorized Organizational Representative (AOR) stipulating to the following points will be required as just-in-time information after review for applications being considering for funding:
- The PD/PI will devote at least 51% of his/her total research effort to this award, inclusive of his/her combined research effort at all institutions where he/she holds an appointment (including foreign institutions). The total research effort should be determined in person-months and should not include time expended toward teaching, administration not directly related to the PD's/PI's research, and/or clinical duties.
- The institution and PD/PI are aware of and accept that other NIGMS research awards, except as allowed in Section I, must be relinquished, and pending NIGMS research applications withdrawn, as a condition of receiving a MIRA.
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the recipient's business official.
Recipients must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.
Any application awarded in response to this FOA will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website. This includes any recent legislation and policy applicable to awards that is highlighted on this website.
Individual awards are based on the application submitted to, and as approved by, the NIH and are subject to the IC-specific terms and conditions identified in the NoA.
ClinicalTrials.gov: If an award provides for one or more clinical trials. By law (Title VIII, Section 801 of Public Law 110-85), the "responsible party" must register and submit results information for certain applicable clinical trials on the ClinicalTrials.gov Protocol Registration and Results System Information Website (https://register.clinicaltrials.gov). NIH expects registration and results reporting of all trials whether required under the law or not. For more information, see https://grants.nih.gov/policy/clinical-trials/reporting/index.htm
Institutional Review Board or Independent Ethics Committee Approval: Recipient institutions must ensure that all protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the recipient must provide NIH copies of documents related to all major changes in the status of ongoing protocols.
Data and Safety Monitoring Requirements: The NIH policy for data and safety monitoring requires oversight and monitoring of all NIH-conducted or -supported human biomedical and behavioral intervention studies (clinical trials) to ensure the safety of participants and the validity and integrity of the data. Further information concerning these requirements is found at http://grants.nih.gov/grants/policy/hs/data_safety.htm and in the application instructions (SF424 (R&R) and PHS 398).
Investigational New Drug or Investigational Device Exemption Requirements: Consistent with federal regulations, clinical research projects involving the use of investigational therapeutics, vaccines, or other medical interventions (including licensed products and devices for a purpose other than that for which they were licensed) in humans under a research protocol must be performed under a Food and Drug Administration (FDA) investigational new drug (IND) or investigational device exemption (IDE).
2. Administrative and National Policy Requirements
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Recipients, and Activities, including of note, but not limited to:
- Federalwide Research Terms and Conditions
- Prohibition on Certain Telecommunications and Video Surveillance Services or Equipment
- Acknowledgment of Federal Funding
If a recipient is successful and receives a Notice of Award, in accepting the award, the recipient agrees that any activities under the award are subject to all provisions currently in effect or implemented during the period of the award, other Department regulations and policies in effect at the time of the award, and applicable statutory provisions.
Should the applicant organization successfully compete for an award, recipients of federal financial assistance (FFA) from HHS must administer their programs in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, disability, age and, in some circumstances, religion, conscience, and sex (including gender identity, sexual orientation, and pregnancy). This includes ensuring programs are accessible to persons with limited English proficiency and persons with disabilities. The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. Please see https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html and https://www.hhs.gov/civil-rights/for-individuals/nondiscrimination/index.html
HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator’s scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research. For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this FOA.
- Recipients of FFA must ensure that their programs are accessible to persons with limited English proficiency. For guidance on meeting the legal obligation to take reasonable steps to ensure meaningful access to programs or activities by limited English proficient individuals see https://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/fact-sheet-guidance/index.html and https://www.lep.gov.
- For information on an institution’s specific legal obligations for serving qualified individuals with disabilities, including reasonable accommodations and making services accessible to them, see http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html.
- HHS funded health and education programs must be administered in an environment free of sexual harassment, see https://www.hhs.gov/civil-rights/for-individuals/sex-discrimination/index.html. For information about NIH's commitment to supporting a safe and respectful work environment, who to contact with questions or concerns, and what NIH's expectations are for institutions and the individuals supported on NIH-funded awards, please see https://grants.nih.gov/grants/policy/harassment.htm.
- For guidance on administering programs in compliance with applicable federal conscience protection and associated anti-discrimination laws see https://www.hhs.gov/conscience/conscience-protections/index.html and https://www.hhs.gov/conscience/religious-freedom/index.html.
Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at https://www.hhs.gov/ocr/about-us/contact-us/index.html or call 1-800-368-1019 or TDD 1-800-537-7697.
In accordance with the statutory provisions contained in Section 872 of the Duncan Hunter National Defense Authorization Act of Fiscal Year 2009 (Public Law 110-417), NIH awards will be subject to the Federal Awardee Performance and Integrity Information System (FAPIIS) requirements. FAPIIS requires Federal award making officials to review and consider information about an applicant in the designated integrity and performance system (currently FAPIIS) prior to making an award. An applicant, at its option, may review information in the designated integrity and performance systems accessible through FAPIIS and comment on any information about itself that a Federal agency previously entered and is currently in FAPIIS. The Federal awarding agency will consider any comments by the applicant, in addition to other information in FAPIIS, in making a judgement about the applicant’s integrity, business ethics, and record of performance under Federal awards when completing the review of risk posed by applicants as described in 45 CFR Part 75.205 and 2 CFR Part 200.206 Federal awarding agency review of risk posed by applicants. This provision will apply to all NIH grants and cooperative agreements except fellowships.
Not Applicable
Data Management and Sharing
Note: The NIH Policy for Data Management and Sharing is effective for due dates on or after January 25, 2023.
Consistent with the NIH Policy for Data Management and Sharing, when data management and sharing is applicable to the award, recipients will be required to adhere to the Data Management and Sharing requirements as outlined in the NIH Grants Policy Statement. Upon the approval of a Data Management and Sharing Plan, it is required for recipients to implement the plan as described.
3. Reporting
When multiple years are involved, recipients will be required to submit the Research Performance Progress Report (RPPR) annually and financial statements as required in the NIH Grants Policy Statement.
a) Under Section B.1 What are the major goals of the project? Note that the goals of the program of research supported by the MIRA are broader than the specific aims of a single project and should be appropriately described. If the goals of the MIRA have changed, complete section B.1.a. Provide a rationale for the changes in the context of the originally proposed research program and give an explanation of how the research continues to fit within NIGMS mission interests.
b) Under Section B4, Opportunities for Training and Professional Development, indicate if individual development plans have been used for any graduate students and/or post-doctoral fellows supported by the award.
c) Under section D.2.c. Changes in Other Support, indicate if there have been changes in Other Support. In addition to the revised Other Support page, include an explanation of how changes in other support relate to the activities supported by the MIRA.
- A final RPPR, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement. NIH FOAs outline intended research goals and objectives. Post award, NIH will review and measure performance based on the details and outcomes that are shared within the RPPR, as described at 45 CFR Part 75.301 and 2 CFR Part 200.301.
- The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for recipients of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All recipients of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.
- In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts from all Federal awarding agencies with a cumulative total value greater than $10,000,000 for any period of time during the period of performance of a Federal award, must report and maintain the currency of information reported in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently FAPIIS). This is a statutory requirement under section 872 of Public Law 110-417, as amended (41 U.S.C. 2313). As required by section 3010 of Public Law 111-212, all information posted in the designated integrity and performance system on or after April 15, 2011, except past performance reviews required for Federal procurement contracts, will be publicly available. Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75 Award Term and Conditions for Recipient Integrity and Performance Matters.
4. Evaluation
In carrying out stewardship of grant programs, NIGMS will periodically evaluate the MIRA program, employing the representative measures identified below. In assessing the effectiveness of research project grant investments, NIGMS may use information from progress reports and public databases, PD/PIs, and from participants themselves. Where necessary, PD/PIs and participants may be appropriately contacted after the completion of the grant period for updates on participants subsequent outcomes. The overall evaluation of the program will be based on metrics that may include, but are not limited to, the following:
- Characteristics of the applicant and awardee pool for the program, such as:
- Geographic distribution
- Investigator demographics
- Institution types
- Scientific topics of supported research
- Indicators of scientific accomplishments / productivity, such as:
- Peer-reviewed research publications and citations
- Patent activity among grantees
We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.
eRA Service Desk (Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threaten submission by the due date, and post-submission issues)
Finding Help Online: http://grants.nih.gov/support/ (preferred method of contact)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)
General Grants Information (Questions regarding application instructions, application processes, and NIH grant resources)
Email: [email protected] (preferred method of contact)
Telephone: 301-480-7075
Grants.gov Customer Support (Questions regarding Grants.gov registration and Workspace)
Contact Center Telephone: 800-518-4726
Email: [email protected]
Baishali Maskeri, Ph.D.
National Institute of General Medical Sciences (NIGMS)
Email: [email protected]
Ashley Barnes, Ph.D.
National Institute of General Medical Sciences (NIGMS)
Email: [email protected]
Maqsood Wani, Ph.D.
Center for Scientific Review (CSR)
Email: [email protected]
Jessica Dean
National Institute of General Medical Sciences (NIGMS)
Email: [email protected]
Leslie Nichols
National Institute of General Medical Sciences (NIGMS)
Email: [email protected]
Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 2 CFR Part 200, 42 CFR Part 52 and 45 CFR Part 75.
and Human Services (HHS)
